Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma (RRMM). The REMIX study is one of the largest prospective, real-world analysis of the effectiveness of IXA-Rd in the sett...

Descripción completa

Detalles Bibliográficos
Autores principales: Macro, M., Hulin, C., Vincent, L., Charvet-Rumpler, A., Benboubker, L., Calmettes, C., Stoppa, A.-M., Laribi, K., Clement-Filliatre, L., Zerazhi, H., Honeyman, F., Richez, V., Maloisel, F., Karlin, L., Barrak, J., Chouaid, C., Leleu, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344838/
https://www.ncbi.nlm.nih.gov/pubmed/37301786
http://dx.doi.org/10.1007/s00277-023-05278-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344838/
https://www.ncbi.nlm.nih.gov/pubmed/37301786
http://dx.doi.org/10.1007/s00277-023-05278-3

Ejemplares similares